Board IPR FWD finding Sanofi’s amended claims not unpatentable affirmed
Mylan Laboratories Limited v. Aventis Pharma S.A.
Docket No. 2020-1302 (IPR2016-00712) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1302.RULE_36_JUDGMENT.1-15-2021_1718184.pdf)
NEWMAN, O’MALLEY, WALLACH
January 15, 2020
Brief Summary: FC panel affirmed Board IPR FWD finding Sanofi’s amended claims not to be unpatentable for obviousness, public use and section 101. Summary: FC panel affirmed Board final written decision (FWD) on remand that was entered on Oct. 22, 2019 (Sanofi Mature IP v. Mylan Labs., FC 2019 (vacating denial of Sanofi’s Motion to Amend (MTA) by introducing new replacement claims 31-34 and remanding)). The FWD relates to US 8,927,592 directed to “[a] method of increasing survival comprising administering”…